192 related articles for article (PubMed ID: 12698073)
1. A substantial level of donor hematopoietic chimerism is required to protect donor-specific islet grafts in diabetic NOD mice.
Guo Z; Wu T; Sozen H; Pan Y; Heuss N; Kalscheuer H; Sutherland DE; Blazar BR; Hering BJ
Transplantation; 2003 Apr; 75(7):909-15. PubMed ID: 12698073
[TBL] [Abstract][Full Text] [Related]
2. Inducing tolerance to MHC-matched allogeneic islet grafts in diabetic NOD mice by simultaneous islet and bone marrow transplantation under nonirradiative and nonmyeloablative conditioning therapy.
Wu T; Levay-Young B; Heuss N; Sozen H; Kirchhof N; Sutherland DE; Hering B; Guo Z
Transplantation; 2002 Jul; 74(1):22-7. PubMed ID: 12134094
[TBL] [Abstract][Full Text] [Related]
3. A more persistent tolerance to islet allografts through bone marrow transplantation in minimal nonmyeloablative conditioning therapy.
Lee BW; Lee JI; Oh SH; Ahn YR; Chae HY; Lee MS; Lee MK; Kim KW
Transplant Proc; 2005 Jun; 37(5):2266-9. PubMed ID: 15964395
[TBL] [Abstract][Full Text] [Related]
4. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice.
Li H; Kaufman CL; Boggs SS; Johnson PC; Patrene KD; Ildstad ST
J Immunol; 1996 Jan; 156(1):380-8. PubMed ID: 8598488
[TBL] [Abstract][Full Text] [Related]
5. Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation.
Elkin G; Prigozhina TB; Slavin S
Exp Hematol; 2004 Jun; 32(6):579-84. PubMed ID: 15183899
[TBL] [Abstract][Full Text] [Related]
6. Nonobese diabetic natural killer cells: a barrier to allogeneic chimerism that can be reduced by rapamycin.
Al-Adra DP; Chan WF; Anderson CC
Transplantation; 2011 Nov; 92(9):977-84. PubMed ID: 21956197
[TBL] [Abstract][Full Text] [Related]
7. Resistance to the induction of mixed chimerism in spontaneously diabetic NOD mice depends on the CD40/CD154 pathway and donor MHC disparity.
Luo B; Wu T; Pan Y; Sozen H; Hao J; Zhang Y; Sutherland DE; Hering BJ; Guo Z
Ann N Y Acad Sci; 2007 Apr; 1103():94-102. PubMed ID: 17376827
[TBL] [Abstract][Full Text] [Related]
8. Robust tolerance to fully allogeneic islet transplants achieved by chimerism with minimal conditioning.
Luo B; Nanji SA; Schur CD; Pawlick RL; Anderson CC; Shapiro AM
Transplantation; 2005 Aug; 80(3):370-7. PubMed ID: 16082333
[TBL] [Abstract][Full Text] [Related]
9. Nonlethal conditioning for the induction of allogeneic chimerism and tolerance to islet allografts.
Li H; Inverardi L; Molano RD; Pileggi A; Ricordi C
Transplantation; 2003 Apr; 75(7):966-70. PubMed ID: 12698081
[TBL] [Abstract][Full Text] [Related]
10. Anti-TCR mAb induces peripheral tolerance to alloantigens and delays islet allograft rejection in autoimmune diabetic NOD mice.
Deng R; Khattar M; Xie A; Schroder PM; He X; Chen W; Stepkowski SM
Transplantation; 2014 Jun; 97(12):1216-24. PubMed ID: 24854475
[TBL] [Abstract][Full Text] [Related]
11. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
Pan Y; Luo B; Sozen H; Kalscheuer H; Blazar BR; Sutherland DE; Hering BJ; Guo Z
Transplantation; 2003 Jul; 76(1):216-24. PubMed ID: 12865813
[TBL] [Abstract][Full Text] [Related]
12. Differential outcomes in prediabetic vs. overtly diabetic NOD mice nonmyeloablatively conditioned with costimulatory blockade.
Bozulic LD; Huang Y; Xu H; Wen Y; Ildstad ST
Exp Hematol; 2011 Oct; 39(10):977-85. PubMed ID: 21726515
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic chimerism induces donor-specific tolerance to simultaneous islet allografts in nonobese diabetic mice.
Li H; Kaufman CL; Ildstad ST
Surgery; 1995 Aug; 118(2):192-7; discussion 197-8. PubMed ID: 7638733
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus-based partial conditioning produces stable mixed lymphohematopoietic chimerism and tolerance for cardiac allografts.
Gammie JS; Li S; Zeevi A; Demetris AJ; Ildstad ST; Pham SM
Circulation; 1998 Nov; 98(19 Suppl):II163-8; discussion II168-9. PubMed ID: 9852899
[TBL] [Abstract][Full Text] [Related]
15. Low levels of allogeneic but not syngeneic hematopoietic chimerism reverse autoimmune insulitis in prediabetic NOD mice.
Kaminitz A; Mizrahi K; Yaniv I; Farkas DL; Stein J; Askenasy N
J Autoimmun; 2009 Sep; 33(2):83-91. PubMed ID: 19632089
[TBL] [Abstract][Full Text] [Related]
16. Development of either split tolerance or robust tolerance along with humoral tolerance to donor and third-party alloantigens in nonmyeloablative mixed chimeras.
Chan WF; Razavy H; Luo B; Shapiro AM; Anderson CC
J Immunol; 2008 Apr; 180(8):5177-86. PubMed ID: 18390699
[TBL] [Abstract][Full Text] [Related]
17. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
18. Distinct requirements for achievement of allotolerance versus reversal of autoimmunity via nonmyeloablative mixed chimerism induction in NOD mice.
Nikolic B; Onoe T; Takeuchi Y; Khalpey Z; Primo V; Leykin I; Smith RN; Sykes M
Transplantation; 2010 Jan; 89(1):23-32. PubMed ID: 20061915
[TBL] [Abstract][Full Text] [Related]
19. Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity.
Nikolic B; Takeuchi Y; Leykin I; Fudaba Y; Smith RN; Sykes M
Diabetes; 2004 Feb; 53(2):376-83. PubMed ID: 14747288
[TBL] [Abstract][Full Text] [Related]
20. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
